Skip to content
Uridine triacetate
Vistogard, Xuriden (uridine triacetate) is a small molecule pharmaceutical. Uridine triacetate was first approved as Xuriden on 2015-09-04. It is used to treat drug overdose in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
chemically-induced disordersD064419
therapeuticsD013812
Trade Name
FDA
EMA
Vistogard, Xuriden
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Uridine triacetate
Tradename
Company
Number
Date
Products
VISTOGARDWellstat TherapeuticsN-208159 RX2015-12-11
1 products, RLD, RS
XURIDENWellstat TherapeuticsN-208169 RX2015-09-04
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vistogardNew Drug Application2018-11-15
xuridenNew Drug Application2019-12-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
drug overdose—D062787—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Uridine Triacetate, Vistogard, Wellstat Therap
77768382027-08-17U-1791
62587952023-07-10DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AX: Various alimentary tract and metabolism products
— A16AX13: Uridine triacetate
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16—1———1
Esophageal neoplasmsD004938C15—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
Mitochondrial diseasesD028361EFO_00005911————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameURIDINE TRIACETATE
INNuridine triacetate
Description
Uridine triacetate is an acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. It has a role as a prodrug, a neuroprotective agent and an orphan drug. It is a member of uridines and an acetate ester.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
Identifiers
PDB—
CAS-ID4105-38-8
RxCUI1665222
ChEMBL IDCHEMBL2107381
ChEBI ID—
PubChem CID20058
DrugBankDB09144
UNII ID2WP61F175M (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 131 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
80 adverse events reported
View more details